Drug intelligence / Profile preview

Fiblyzyme

Development stage: Unknown
Lead developer: West China Hospital of Sichuan University
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Fiblyzyme is an investigational pharmaceutical drug being developed for the treatment of acute ischemic stroke. It is a fibrinolytic enzyme, meaning it functions by breaking down fibrin clots that obstruct blood flow in ischemic stroke. The drug is administered via intravenous drip. It is currently undergoing a multi-center, randomized, blind, placebo-controlled clinical trial by West China Hospital, Sichuan University and Beijing Saisheng Pharmaceutical Co., Ltd.

Targets

Fibrin (Factor Ia)

Beyond the preview

Go deeper on Fiblyzyme.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fiblyzyme.

Explore the full profile